Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Professor Will Herrington

Professor Will Herrington

Will Herrington


Professor of Trials and Epidemiology of Kidney Disease, Renal Studies Group

  • Professor of Trials and Epidemiology of Kidney Disease
  • Honorary Consultant Nephrologist, Oxford Kidney Unit


Professor Will Herrington is a clinician scientist based at the Nuffield Department of Population Health, University of Oxford and a practising Honorary Consultant Nephrologist at Oxford Kidney Unit. He jointly leads the Renal Studies Group which he joined in 2010 as a Clinical Research Fellow and trained on landmark renal trials (SHARP, 3C and UKHARP3).

He is Chief Investigator of the EASi-KIDNEY trial (which is due to start recruitment in 2024) and the EMPA-KIDNEY trial which tested the effects of empagliflozin 10mg versus placebo on cardiorenal outcomes in 6609 people with chronic kidney disease with and without diabetes.

The trial has now entered a post-trial observational follow-up phase and is developing health economic analyses. The biobank of leftover biological samples is being analysed to better understand the mechanism of action and metabolic effects of sodium glucose co-transporter-2 (SGLT-2) inhibitors like empagliflozin.

He has participated on a number of clinical practice guideline working groups, including with the European Society of Cardiology, UK Kidney Association, and K/DIGO. He is also interested in trial methodology and chaired the UK Renal Trials Network from 2020 2024.

His epidemiological research aims to better understand the key determinants of kidney disease development and progression (and its associated complications) using observations from large blood-based prospective cohorts across a wide range of different populations.

He has a particular focus on adiposity and its related risk factors, and how these may interlink to also cause cardiovascular disease. He is also focusing on how novel urine biomarkers could better assess effects of treatments on the kidney and predict progression.

Key publications

Recent publications

More publications